Davis R M Inc. decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 6.5% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 6,859 shares of the medical equipment provider’s stock after selling 480 shares during the period. Davis R M Inc.’s holdings in Hologic were worth $555,000 at the end of the most recent reporting period.
Other hedge funds have also added to or reduced their stakes in the company. Bank Julius Baer & Co. Ltd Zurich lifted its stake in Hologic by 98,061.1% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 22,086,241 shares of the medical equipment provider’s stock worth $1,788,323,000 after purchasing an additional 22,063,741 shares during the last quarter. Macquarie Group Ltd. lifted its position in shares of Hologic by 227.2% during the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock worth $435,485,000 after buying an additional 4,363,687 shares during the last quarter. Wellington Management Group LLP boosted its stake in Hologic by 80.0% in the first quarter. Wellington Management Group LLP now owns 8,984,757 shares of the medical equipment provider’s stock valued at $725,070,000 after buying an additional 3,992,822 shares in the last quarter. Norges Bank bought a new position in Hologic in the fourth quarter valued at about $175,900,000. Finally, Envestnet Asset Management Inc. raised its stake in Hologic by 506.3% during the first quarter. Envestnet Asset Management Inc. now owns 1,711,592 shares of the medical equipment provider’s stock worth $29,345,000 after acquiring an additional 1,429,300 shares in the last quarter. 92.64% of the stock is owned by institutional investors.
Hologic Stock Performance
NASDAQ:HOLX opened at $71.90 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.95 and a current ratio of 3.47. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88. The company has a 50 day simple moving average of $69.42 and a two-hundred day simple moving average of $75.31. The company has a market capitalization of $17.61 billion, a PE ratio of 39.29, a P/E/G ratio of 2.34 and a beta of 1.03.
Analyst Ratings Changes
Several brokerages recently issued reports on HOLX. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Friday, November 10th. TheStreet downgraded shares of Hologic from a “b” rating to a “c+” rating in a report on Monday, July 31st. Needham & Company LLC cut their price objective on Hologic from $95.00 to $83.00 and set a “buy” rating on the stock in a report on Thursday, October 26th. UBS Group lowered their target price on Hologic from $91.00 to $78.00 and set a “neutral” rating for the company in a report on Thursday, November 16th. Finally, Citigroup dropped their target price on Hologic from $90.00 to $85.00 and set a “neutral” rating for the company in a research report on Tuesday, August 1st. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.58.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
- Five stocks we like better than Hologic
- How to Use the MarketBeat Dividend Calculator
- Safeguard your portfolio with these three bargain stocks
- Best Stocks Under $5.00
- Membership clubs gain leverage for the consumer rebound
- What Does the Consumer Price Index Measure?
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.